Drugs / NanoLithium® NP03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05423522 | May 2022 → Jan 2024 | Alzheimer disease | Medesis Pharma SA | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanoLithium NP03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05423522 ↗ |